Bridge GLP compliant drug development in China

Services

Globally Integrated Preclinical Services

Species

Bridge develops safe and ground breaking new medicines for the pharmaceutical and biotechnology industries through preclinical contract research laboratory in China.  Bridge strives for excellence by providing our clients with studies of sound science, technical proficiency, quality assurance, integrity, and speed of process. 

Preclinical Services Portfolio

Bridge helps clients plan and conduct safety assessment studies to assist compound development programs involving small molecules, biologics, neutraceuticals, vaccines, chemicals, and intermediates.  We conduct short and long-term in vivo studies, from acute to carcinogenicity protocols. 

Routes of Administration

Globally Cost-Effective Service in China

Our China capabilities include most aspects of preclinical discovery and development services.  Bridge has one of the largest and most sophisticated animal vivariums in China.  This facility was designed from the ground up to be operated as AAALAC and US-level GLP compliant.  Bridge employees are extensively trained and certified in a variety of programs involving US-level quality assurance, and technical training.  Bridge employs state-of the-art encryption and other data security methods to protect intellectual property.  Animals are exclusively supplied from US-franchised animal breeders, the only two in China.  This provides the confidence of genetic homogeneity to animal models used in the US and Europe.

First of Its Kind in Asia

Bridge is the first Asian preclinical CRO with western-level attention to detail worthy of any state-of-the-art facility, including

Fully Accredited Facilities

Our technical proficiency, speed, and regulatory expertise; ensure that you receive quality and timely information in support of your regulatory submissions.  Never before have you been offered the same high-quality services, at competitive prices from a service provider in Asia.